CCM
APLT

Connective Capital Management’s Applied Therapeutics APLT Stock Holding History

Connective Capital Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-79,242
Closed -$265K – 32
2023
Q4 		$265K Buy
+79,242
New +$197K 0.22% 58

Other funds holding APLT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Connective Capital Management's APLT Position: Q1 2024 in Review

Connective Capital Management sold out of Applied Therapeutics (APLT) in Q1 2024, closing a stake of 79,242 shares — an estimated $265K sold.

Connective Capital Management first reported a position in APLT in Q4 2023 and held it in 1 quarter. The position peaked at $265K in Q4 2023. 89 funds tracked by Wall St. Rank hold APLT as of Q1 2024.

  • Connective Capital Management reported no remaining Applied Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Connective Capital Management sold 79,242 Applied Therapeutics shares in Q1 2024, an estimated $265K.
  • Connective Capital Management first reported a position in Applied Therapeutics in Q4 2023 and held it in 1 quarter.
  • Connective Capital Management's Applied Therapeutics position peaked at $265K in Q4 2023.
  • 89 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2024.

Based on Connective Capital Management's 13F filing for Q1 2024, filed 16 May 2024.